Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling

BACKGROUND: Lovastatin, an HMG-CoA inhibitor and an effective cholesterol lowering drug, exhibits anti-neoplastic activity towards several types of cancer, although the underlying mechanism is still not fully understood. Herein, we investigated mechanism of growth inhibition of leukemic cells by lov...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jian, Hu, Jifen, Yu, Fang, Wang, Chunlin, Sheng, Danmei, Liu, Wuling, Hu, Anling, Yu, Kunling, Xiao, Xiao, Kuang, Yi, Zacksenhaus, Eldad, Gajendran, Babu, Ben-David, Yaacov
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071686/
https://www.ncbi.nlm.nih.gov/pubmed/37016335
http://dx.doi.org/10.1186/s12885-023-10742-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071686/
https://www.ncbi.nlm.nih.gov/pubmed/37016335
http://dx.doi.org/10.1186/s12885-023-10742-4

Ejemplares similares